What is Evaxion Biotech AS?
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 20.75M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.